Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRPT vs BHVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHVN Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)

BHVN Overall Winner 6-Pillar Tally: SRPT 3 – 3 BHVN Matrix Metrics: SRPT 3 – 6 BHVN

As of Nov 16, 2026, Biohaven Ltd. (BHVN) is the stronger overall head-to-head candidate over Sarepta Therapeutics,, Inc. (SRPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SRPT carries a Unified Composite Score of 37.8/100 (SELL) at $15.25 (10.8x Forward P/E, -0.4% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRPT vs BHVN
SRPT NASDAQ
Sarepta Therapeutics,, Inc. Common Stock
Pharmaceutical Preparations
$15.25
-5.1% 1D
Market Cap $1.7B
TTM Revenue $1.96B
Forward P/E 10.8x
Beta / 30D Vol 1.48β · 59% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 32.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.9%), weak momentum, RSI 33
RSI-14: 33.0 · SMA20: $17.82 · SMA50: $18.44
BHVN NYSE Head-to-Head Winner
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.40β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48

6-Pillar Scorecard Institutional Category Breakdown (SRPT 3 – 3 BHVN)

Columns: Metric · SRPT · BHVN
1. Valuation Multiples SRPT
Forward P/E 10.8x N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.2x N/M
2. Growth & Scale BHVN
Revenue Growth (YoY) -4.5% +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $1.96B N/A
Market Cap $1.7B $2.1B
3. Profitability & Quality BHVN
Gross Margin 23.4% N/A
Operating Margin -0.4% 0.0%
Net Profit Margin -5.9% 0.0%
Return on Equity (ROE) -8.1% -799.5%
4. Balance Sheet & Cash Flow SRPT
Cash Generation (TTM) $172M -$473M
Cash Flow Margin 8.8% N/A
Net Cash / Leverage $580M Net Debt (0.69x D/E) $205M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHVN
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 54.5% (7th %ile) 91.5% (18th %ile)
Put/Call OI Skew 0.66x (Call-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat SRPT
OpEx & R&D Intensity 23.8% of Rev ($466M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRPT (3) vs BHVN (6)
Institutional Metric SRPT BHVN Criterion Row Edge
Market Capitalization
Scale
$1.7B $2.1B Larger Scale BHVN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
10.8x N/M Lower Multiple SRPT
Revenue Growth (YoY)
Growth
-4.5% +0.0% Higher Growth BHVN
Operating Margin (TTM)
Profitability
-0.4% 0.0% Higher Margin BHVN
Net Profit Margin
Profitability
-5.9% 0.0% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-8.1% -799.5% Higher ROE SRPT
52-Week Range Position
Momentum
6% ($15–$25) 59% ($8–$18) Stronger Trend BHVN
Beta / 30D Volatility
Risk Regime
1.48β · 59% Vol 1.40β · 111% Vol Lower Realized Risk SRPT
Unified Institutional Score
Composite Signal
37.8 / 100 (SELL) 42.1 / 100 (HOLD) Higher Composite BHVN
Trailing 12M Revenue (USD)
Operating Scale
$1.96B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$172M ($580M Net Debt (0.69x D/E)) -$473M ($205M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +40.18 pp
SRPT: -10.82% · BHVN: +29.36%
3M Horizon BHVN +18.13 pp
SRPT: -15.37% · BHVN: +2.76%
6M Horizon BHVN +74.6 pp
SRPT: -10.35% · BHVN: +64.25%
1Y Horizon BHVN +87.01 pp
SRPT: -14.42% · BHVN: +72.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRPT vs BHVN. Trailing 12-month operating profitability (SRPT -0.4% vs BHVN 0.0%) and valuation multiples (SRPT 10.8x vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SRPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.96B
Gross Margin23.4%
Op. Margin-0.4%
ROE / Fwd P/E-8.1% · 10.8x
BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRPT BREAKDOWN
52d in phase · OBV DISTRIBUTION
Current IV 54.5%
IV Percentile 7th %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SRPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($466M)
90D Engineering Disclosures 0 Published
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRPT vs BHVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Biohaven Ltd. (BHVN) is the stronger overall head-to-head candidate over Sarepta Therapeutics,, Inc. (SRPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SRPT carries a Unified Composite Score of 37.8/100 (SELL) at $15.25 (10.8x Forward P/E, -0.4% operating margin), whereas BHVN carries 42.1/100 (HOLD) at $13.95 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHVN leads the Growth & Scale pillar: SRPT posts -4.5% YoY revenue growth and N/A YoY earnings growth on $1.96B TTM revenue (23.4% gross margin, -0.4% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SRPT generates $1.96B in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, SRPT deploys 23.8% of Rev ($466M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.

SRPT screens cheaper on headline valuation multiples. SRPT trades at 10.8x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (8.8% FCF margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRPT (-8.1% ROE) versus BHVN (-799.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SRPT carries 54.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 59% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.40β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.